May 4, 2015 – With extensive experience guiding biotech companies in matters including corporate development and clinical strategy, Dr. Garceau’s appointment strengthens Fluorinov’s leadership team and adds significant regulatory expertise as Fluorinov transitions to clinical development.
Category: Uncategorized
Xagenic Announces Second Closing of $25.5M Series B Financing
July 14, 2014 – BDC Capital joined as a new investor and Dion Madsen, Senior Managing Partner at BDC Capital, will join Xagenic’s Board of Directors.
Read More from Xagenic Announces Second Closing of $25.5M Series B Financing
XLV Diagnostics Inc. secures a $3 Million Series A investment
May 28, 2014 – XLV, a MaRS Innovation start-up company based in Thunder Bay, closed a $3 million Series A investment round with Boston-based Bernard M. Gordon Charitable Remainder Unitrust.
Read More from XLV Diagnostics Inc. secures a $3 Million Series A investment
Fluidigm Completes Acquisition of DVS Sciences
February 13, 2014 – With the closing of the acquisition, Fluidigm adds a high-parameter single-cell protein analysis platform to its industry-leading single-cell genomics platforms.
Read More from Fluidigm Completes Acquisition of DVS Sciences
Triphase Signs Collaboration and Option Agreement with Celgene Corporation
January 9, 2014 – Triphase was spun out of the Ontario Institute for Cancer Research to develop and advance late pre-clinical, Phase I or early Phase II potential products.
Read More from Triphase Signs Collaboration and Option Agreement with Celgene Corporation
OICR and MaRS Innovation announce funding for the development of Cellax™
November 13, 2012 – Cellax™, invented by OICR researchers, is a drug-polymer conjugate based on the proprietary NanoCMC™ technology.
Read More from OICR and MaRS Innovation announce funding for the development of Cellax™
Fluorinov Pharma Inc. develops drug for the treatment of blood cancers
June 7, 2012 – OICR will provide $1.5 million for the development of FV-162, a highly potent, orally-delivered small molecule proteasome inhibitor for multiple myeloma and some forms of Non-Hodgkin’s lymphoma.
Read More from Fluorinov Pharma Inc. develops drug for the treatment of blood cancers
Xagenic Inc. Raises $10 Million to Advance Commercialization of Breakthrough Screening Technology
January 30, 2012 – Investors in the Series A round included CTI Life Sciences Fund L.P., Qiagen N.V. and Ontario Capital Growth Corporation through its Emerging Technologies Fund.
Triphase Accelerator Corporation Announces Expansion of Collaboration with Celgene
May 3, 0206 – Triphase is expanding its current collaboration with Celgene in the development of marizomib for the potential treatment of malignant gliomas.
Read More from Triphase Accelerator Corporation Announces Expansion of Collaboration with Celgene